We are a team!

PubMedID: 30361760[No abstract available

Denosumab in the treatment of glucocorticoid-induced osteoporosis

PubMedID: 30019224Glucocorticoid therapy is the number one cause of secondary osteoporosis particularly effecting young individuals. Possessing an increased risk for fractures, glucocorticoid-induced osteoporosis might interfere with patients’ well-being and quality of life. Therefore, proper treatment of bone loss and prevention from fractures are of great importance. There are a limited number of therapeutic and preventative options for glucocorticoid-induced osteoporosis. Denosumab, with its high anti-resorptive potential, has been studied several times among patients on glucocorticoid therapy. However, a comprehensive look analysing the current data is lacking. Thus, the objective of the current article is to evaluate the current evidence on the efficacy, as well as the safety profile of denosumab in glucocorticoid-induced osteoporosis. Pubmed/MEDLINE, Scopus and Web of Science databases were searched for the terms denosumab, glucocorticoid-induced osteoporosis, steroid-induced osteoporosis, glucocorticoids and osteoporosis. Relevant data regarding the efficacy and safety of denosumab among patients with glucocorticoid-induced osteoporosis was analysed. Denosumab contributes to increased bone mineral density and decreased bone-turnover marker levels among glucocorticoid users. It is an effective therapeutic option with a favourable safety profile in glucocorticoid-induced osteoporosis. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature

Polypharmacy in geriatric rheumatology

PubMedID: 30810781[No abstract available

Role of inflammation in the pathogenesis and treatment of fibromyalgia

PubMedID: 30756137Fibromyalgia is a multifaceted disease. The clinical picture of fibromyalgia covers numerous comorbidities. Each comorbidity stands as a distinct condition. However, common pathophysiologic factors are occupied in their background. Along with the genetic, environmental and neuro-hormonal factors, inflammation has been supposed to have role in the pathogenesis of fibromyalgia. The aim of the present article was to review the current literature regarding the potential role of inflammation in the pathogenesis and treatment of fibromyalgia. A literature search was conducted through PubMed/MEDLINE and Web of Science databases using relevant keywords. Recent evidence on this highly studied topic indicates that fibromyalgia has an immunological background. Cytokines/chemokines, lipid mediators, oxidative stress and several plasma-derived factors underlie the inflammatory state in fibromyalgia. There are potential new therapeutic options targeting inflammatory pathways in fibromyalgia patients. In conclusion, there is evidence to support the inflammation-driven pathways in the pathogenesis of fibromyalgia. However, further research is required to fully understand the network of inflammation and its possible role in diagnosis and/or treatment of fibromyalgia. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature

Think twice before submitting your precious articles for publication!

[No abstract available

Visibility of scientific work

[No abstract available

Let us take care of the patient!

PubMedID: 30306252Treating the patient—not only the disease itself—is important in daily clinical practice. Herein, a short text and a related cartoon on patient care are provided. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature

Reliability of real-world data

PubMedID: 30604203[No abstract available

The secrets of keeping fit: exercising and healthy eating

PubMedID: 30306253Physical fitness not only requires exercising, but also healthy eating habits. Herein, a cartoon and a related text on physical fitness are submitted. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature